These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 19594950)

  • 1. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.
    Sei S; Mussio JK; Yang QE; Nagashima K; Parchment RE; Coffey MC; Shoemaker RH; Tomaszewski JE
    Mol Cancer; 2009 Jul; 8():47. PubMed ID: 19594950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
    Feng F; Wang B; Sun X; Zhu Y; Tang H; Nan G; Wang L; Wu B; Huhe M; Liu S; Diao T; Hou R; Zhang Y; Zhang Z
    Cancer Biol Ther; 2017 Jan; 18(1):51-62. PubMed ID: 28055291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.
    Greer RM; Peyton M; Larsen JE; Girard L; Xie Y; Gazdar AF; Harran P; Wang L; Brekken RA; Wang X; Minna JD
    Cancer Res; 2011 Dec; 71(24):7640-8. PubMed ID: 22049529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.
    Patel MR; Jacobson BA; Belgum H; Raza A; Sadiq A; Drees J; Wang H; Jay-Dixon J; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
    J Thorac Oncol; 2014 Aug; 9(8):1101-10. PubMed ID: 25157763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.
    Jiang Y; Dai H; Li Y; Yin J; Guo S; Lin SY; McGrail DJ
    Int J Cancer; 2019 Mar; 144(5):1092-1103. PubMed ID: 30152517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel.
    Mato-Berciano A; Raimondi G; Maliandi MV; Alemany R; Montoliu L; Fillat C
    Oncotarget; 2017 Apr; 8(14):22700-22715. PubMed ID: 28186974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
    Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
    Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
    Jacob DA; Bahra M; Langrehr JM; Boas-Knoop S; Stefaniak R; Davis J; Schumacher G; Lippert S; Neumann UP
    J Gastroenterol Hepatol; 2007 May; 22(5):738-48. PubMed ID: 17444865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synergistic anticancer effects of ReoT3D, CPT-11, and BBI608 on murine colorectal cancer cells.
    Babaei A; Soleimanjahi H; Soleimani M; Arefian E
    Daru; 2020 Dec; 28(2):555-565. PubMed ID: 32803686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.
    Zhang L; Qi Y; Xing K; Qian S; Zhang P; Wu X
    Oncol Rep; 2018 Aug; 40(2):1046-1054. PubMed ID: 29917169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
    Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
    Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.
    Karapanagiotou EM; Roulstone V; Twigger K; Ball M; Tanay M; Nutting C; Newbold K; Gore ME; Larkin J; Syrigos KN; Coffey M; Thompson B; Mettinger K; Vile RG; Pandha HS; Hall GD; Melcher AA; Chester J; Harrington KJ
    Clin Cancer Res; 2012 Apr; 18(7):2080-9. PubMed ID: 22316603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stem cells loaded with oncolytic reovirus enhances antitumor activity in mice models of colorectal cancer.
    Babaei A; Soleimanjahi H; Soleimani M; Arefian E
    Biochem Pharmacol; 2021 Aug; 190():114644. PubMed ID: 34090878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.
    Srirangam A; Milani M; Mitra R; Guo Z; Rodriguez M; Kathuria H; Fukuda S; Rizzardi A; Schmechel S; Skalnik DG; Pelus LM; Potter DA
    J Thorac Oncol; 2011 Apr; 6(4):661-70. PubMed ID: 21270666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.
    Villalona-Calero MA; Lam E; Otterson GA; Zhao W; Timmons M; Subramaniam D; Hade EM; Gill GM; Coffey M; Selvaggi G; Bertino E; Chao B; Knopp MV
    Cancer; 2016 Mar; 122(6):875-83. PubMed ID: 26709987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
    Xie CY; Xu YP; Jin W; Lou LG
    Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
    Bradbury PA; Morris DG; Nicholas G; Tu D; Tehfe M; Goffin JR; Shepherd FA; Gregg RW; Rothenstein J; Lee C; Kuruvilla S; Keith BD; Torri V; Blais N; Hao D; Korpanty GJ; Goss G; Melosky BL; Mates M; Leighl N; Ayoub JP; Sederias J; Feilotter H; Seymour L; Laurie SA
    Lung Cancer; 2018 Jun; 120():142-148. PubMed ID: 29748010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of docetaxel in advanced non-small-cell lung cancer.
    Belani CP; Eckardt J
    Lung Cancer; 2004 Dec; 46 Suppl 2():S3-11. PubMed ID: 15698529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
    Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
    Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
    Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
    Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.